[1]黄照茹,张连峰,周 琳#.阿昔替尼联合塞来昔布体外抗胃癌细胞BGC-823和SNU-5增殖及抗血管生成作用观察[J].郑州大学学报(医学版),2017,(01):34-36.[doi:10.13705/j.issn.1671-6825.2017.01.009]
 HUANG Zhaoru,ZHANG Lianfeng,ZHOU Lin.Combination efficacy of axitinib and celecoxib on proliferation of gastric cancer cells BGC-823 and SNU-5 and its antiangiogenesis effect[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(01):34-36.[doi:10.13705/j.issn.1671-6825.2017.01.009]
点击复制

阿昔替尼联合塞来昔布体外抗胃癌细胞BGC-823和SNU-5增殖及抗血管生成作用观察()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2017年01期
页码:
34-36
栏目:
论著
出版日期:
2017-01-15

文章信息/Info

Title:
Combination efficacy of axitinib and celecoxib on proliferation of gastric cancer cells BGC-823 and SNU-5 and its antiangiogenesis effect
作者:
黄照茹张连峰周 琳#
郑州大学第一附属医院消化内科 郑州 450052
Author(s):
HUANG ZhaoruZHANG LianfengZHOU Lin
Department of Gastroenterology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052
关键词:
塞来昔布 阿昔替尼 胃癌 联合用药 BGC-823细胞 SNU-5细胞
Keywords:
celecoxib axitinib gastric cancer combination therapy BGC-823 cell SNU-5 cell
分类号:
R735.2
DOI:
10.13705/j.issn.1671-6825.2017.01.009
摘要:
目的:探索阿昔替尼(Ax)和塞来昔布(Cel)在胃癌细胞株BGC-823和SNU-5的联合效应及对新生血管形成的影响。方法:SRB法测定10 nmol/L Cel和1 nmol/L Ax以及联合用药对BGC-823细胞增殖的抑制作用,CCK-8法检测Cel和Ax以及联合用药对SNU-5细胞增殖的抑制作用,Matrial胶体外管腔形成法检测药物对于新生血管的影响。结果:在BGC-823和SNU-5细胞株中,Cel和Ax单药均可抑制BGC-823和SNU-5细胞的增殖,联合用药组的细胞生长抑制率高于Cel和Ax单药组,联合用药指数<1。Cel和Ax单药组对HUVEC细胞的管腔形成系数分别为(0.86±0.03)和(0.83±0.01),联合这2种药物之后,管腔形成系数下降为(0.67±0.02)(P<0.05)。结论:Cel和Ax的联合用药方案不仅比单一用药有更高的细胞生长抑制率,并且还具有协同抑制新生血管形成的作用。
Abstract:
Aim: To explore the combination efficacy of axitinib(Ax)and celecoxib(Cel)on the proliferation of gastric cancer cell lines BGC-823 and SNU-5 and antiangiogenesis effect.Methods: SRB and CCK-8 methods were used to assess the effect of 10 nmol/L Cel and 1 nmol/L Ax on the proliferation of BGC-823 and SNU-5,respectively. Capillary formation was detected by Matrial-plug assay in vitro.Results: SRB and CCK-8 assay showed that Cel and Ax inhibited the proliferation of BGC-823 and SNU-5. The inhibitory rate of combined treatment with Cel and Ax was significantly higher than that of Cel or Ax alone,and the combination index was lower than 1. The vascular indexes of HUVEC treated by Cel and Ax were(0.86±0.03)and(0.83±0.01), respectively, while the combined treatment group was(0.67±0.02)(P<0.05).Conclusion: The combination therapy of Ax and Cel reveals synergetic effect not only in the cell proliferation but also in angiogenesis inhibition.

参考文献/References:

[1] FERLAY J,SHIN HR,BRAY F,et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893
[2] YU J,GAO J,LU Z,et al.Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine[J].Med Oncol,2012,29(5):3029
[3] QIU ZQ,QIU ZR.Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression[J].Asian Pac J Cancer Prev,2015,16(8):3447
[4] SIERRA JC,HOBBS S,CHATURVEDI R,et al.Induction of COX-2 expression by Helicobacter pylori is mediated by activation of epidermal growth factor receptor in gastric epithelial cells[J].Am J Physiol Gastrointest Liver Physiol,2013,305(2):G196
[5] LIU J,HUANG XE,TIAN GY,et al.Phase Ⅱ study on safety and efficacy of Yadanzi(Javanica oil emulsion injection)combined with chemotherapy for patients with gastric cancer[J].Asian Pac J Cancer Prev,2013,14(3):2009
[6] XU HB,SHEN FM,LV QZ.Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2[J].Eur J Pharmacol,2015,769:1
[7] KOIZUMI W,NARAHARA H,HARA T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial): a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215
[8] JOO YE,CHUNG IJ,PARK YK,et al.Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer[J].J Korean Med Sci,2006,21(5):871
[9] KIM YY,LEE EJ,KIM YK,et al.Anti-cancer effects of celecoxib in head and neck carcinoma[J].Mol Cells,2010,29(2):185

备注/Memo

备注/Memo:
#通信作者,女,1977年7月生,博士,副主任医师,副教授,研究方向:胰腺疾病的基础与临床,E-mail:ZL372@126.com
更新日期/Last Update: 2017-01-20